MetaVia Inc
Company Profile
Business description
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Contact
545 Concord Avenue
Suite 210
CambridgeMA02138
USAT: +1 857 702-9600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,768.60 | 1.60 | -0.02% |
| CAC 40 | 7,790.27 | 14.40 | -0.18% |
| DAX 40 | 24,323.58 | 47.10 | 0.19% |
| Dow JONES (US) | 42,319.74 | 108.00 | -0.25% |
| FTSE 100 | 8,811.04 | 9.75 | 0.11% |
| HKSE | 23,906.97 | 252.94 | 1.07% |
| NASDAQ | 19,298.45 | 162.04 | -0.83% |
| Nikkei 225 | 37,554.49 | 192.96 | -0.51% |
| NZX 50 Index | 12,577.15 | 82.44 | 0.66% |
| S&P 500 | 5,939.30 | 31.51 | -0.53% |
| S&P/ASX 200 | 8,538.90 | 2.90 | -0.03% |
| SSE Composite Index | 3,384.10 | 7.90 | 0.23% |